SUBSCRIBE
SUBSCRIBE

Canada

MORE FROM BIOSPACE INSIGHTS
Novartis head office building in Dorval, Quebec, Canada
Business
Novartis, Versant Launch RNA Kidney Medicines—Focused Borealis
Looking to build on the success of Chinook Therapeutics, founded by Versant in 2019 and acquired by Novartis last year, the companies on Thursday launched Borealis Biosciences with $150 million in funding to develop RNA therapeutics for kidney diseases.
August 22, 2024
 · 
2 min read
 · 
Kate Goodwin
Agilent's signage at its office in California
Mergers & acquisitions
Agilent Pays $925M to Buy CDMO Biovectra to Boost Biologics, CRISPR Capabilities
The acquisition of the contract development and manufacturing organization will allow Agilent Technologies to provide a one-stop source for gene-editing services for its customers.
July 23, 2024
 · 
2 min read
 · 
Tristan Manalac
PRESS RELEASES
Business
VALEO PHARMA REPORTS THIRD QUARTER 2024 REVENUES
September 12, 2024
 · 
8 min read
Business
NurExone Biologic Extends Global Reach with Presentations at Industry-Leading Conferences
September 12, 2024
 · 
10 min read
Press Releases
Sernova Announces New Positive Data from Phase I/II Trial Regarding Islet Survival and Function
September 12, 2024
 · 
8 min read
Press Releases
Crescita to Present & Participate in 1x1 Meetings at the Planet MicroCap Showcase: VANCOUVER 2024 in Association with Small Cap Discoveries on Thursday, September 26, 2024
September 12, 2024
 · 
2 min read
Press Releases
ProMIS Neurosciences to Showcase PMN310’s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences
September 12, 2024
 · 
6 min read
Press Releases
Health Canada Approves KEYTRUDA® as monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumours that have progressed following prior treatment and who have no satisfactory alternative treatment options
September 12, 2024
 · 
6 min read
Press Releases
ASTRAZENECA CANADA PARTNERS WITH THE LEUKEMIA & LYMPHOMA SOCIETY OF CANADA TO DRIVE CHANGE IN BLOOD CANCER RESEARCH
September 12, 2024
 · 
4 min read
Press Releases
Kane Biotech Announces Exercise of Warrants
September 12, 2024
 · 
2 min read
Press Releases
Epitopea Awarded Grant from Innovate UK’s Cancer Therapeutics Programme
September 12, 2024
 · 
3 min read
Press Releases
Syantra Secures $4.9 Million in Series A-1 Funding; Adds Dr. Rick Mangat to Board of Directors
September 12, 2024
 · 
4 min read
Press Releases
PlasCred Circular Innovations Inc. Announces Commercial Scaling of PlasCred Primus, PlasCred Neos FEED Study Update and Q2 2024 Results
September 11, 2024
 · 
8 min read
Press Releases
Braxia Announces Annual General and Special Meeting
September 11, 2024
 · 
4 min read
Business
BriaCell Therapeutics Announces $8.5 Million Offering
September 11, 2024
 · 
4 min read
Press Releases
PharmAla to supply Johns Hopkins Medicine for Clinical Trial
September 11, 2024
 · 
4 min read
Press Releases
BriaCell Reports Positive Overall Survival (OS) in Metastatic Breast Cancer
September 11, 2024
 · 
7 min read
Press Releases
Health Canada Approves (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide) Triple-Combination Topical Treatment for Acne Vulgaris in Patients 12 Years of Age and Older
September 11, 2024
 · 
7 min read
Press Releases
Eupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
September 11, 2024
 · 
12 min read
Press Releases
Radiant Bio Closes $35 Million Series A Financing to Advance Therapeutic Pipeline with Its Proprietary Multabody™ Platform
September 11, 2024
 · 
4 min read
Press Releases
Arch Biopartners Announces Alberta Health Services Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)
September 11, 2024
 · 
5 min read
Press Releases
Pendopharm announces public drug coverage plan listings for Octasa® (oral mesalamine)
September 11, 2024
 · 
3 min read
Load More